Genta Announces Second Quarter 2008 Financial Results and Conference Call
31 Julio 2008 - 7:00AM
PR Newswire (US)
BERKELEY HEIGHTS, N.J., July 31 /PRNewswire-FirstCall/ -- Genta
Incorporated (OTC:GNTA) (BULLETIN BOARD: GNTA) announced today that
the Company will release its second quarter 2008 financial results
on Thursday, August 7, 2008. Genta management will host a
conference call and live audio webcast to discuss these financial
results and corporate activities at 8:00 am EDT. Participants can
access the live call by dialing (877) 634-8606 (U.S. and Canada) or
(706) 679-3140 (International). The access code for the live call
is Genta Incorporated. The call will also be webcast live at
http://www.genta.com/investorrelation/events.html For investors
unable to participate in the live call, a replay will be available
approximately two hours after the completion of the call, and will
be archived for 30 days. Access numbers for this replay are: (800)
642-1687 (U.S. and Canada) and (706) 645-9291 (International);
conference ID number is 57549066. About Genta Genta Incorporated is
a biopharmaceutical company with a diversified product portfolio
that is focused on delivering innovative products for the treatment
of patients with cancer. Two major programs anchor the Company's
research platform: DNA/RNA-based Medicines and Small Molecules.
Genasense(R) (oblimersen sodium) Injection is the Company's lead
compound from its DNA/RNA Medicines program. Genta is currently
recruiting patients to the AGENDA Trial, a global Phase 3 trial of
Genasense in patients with advanced melanoma. The leading drug in
Genta's Small Molecule program is Ganite(R) (gallium nitrate
injection), which the Company is exclusively marketing in the U.S.
for treatment of symptomatic patients with cancer-related
hypercalcemia that is resistant to hydration. The Company has
developed G4544, an oral formulation of the active ingredient in
Ganite, that has recently entered clinical trials as a potential
treatment for diseases associated with accelerated bone loss. The
Company is also developing tesetaxel, a novel, orally absorbed,
semi-synthetic taxane that is in the same drug class as paclitaxel
and docetaxel. Ganite and Genasense are available on a
"named-patient" basis in countries outside the United States. For
more information about Genta, please visit our website at:
http://www.genta.com/. Safe Harbor This press release may contain
forward-looking statements with respect to business conducted by
Genta Incorporated. By their nature, forward-looking statements and
forecasts involve risks and uncertainties because they relate to
events and depend on circumstances that will occur in the future.
Forward-looking statements include, without limitation, statements
about: -- the Company's ability to obtain necessary regulatory
approval for Genasense(R) from the U.S. Food and Drug
Administration ("FDA") or European Medicines Agency ("EMEA"); --
the safety and efficacy of the Company's products or product
candidates; -- the Company's assessment of its clinical trials; --
the commencement and completion of clinical trials; -- the
Company's ability to develop, manufacture, license and sell its
products or product candidates; -- the Company's ability to enter
into and successfully execute license and collaborative agreements,
if any; -- the adequacy of the Company's capital resources and cash
flow projections, the Company's ability to obtain sufficient
financing to maintain the Company's planned operations, or the
Company's risk of bankruptcy if it is unsuccessful in obtaining
such financing or in securing shareholder approval to increase the
number of shares authorized for issuance under the Company's
certificate of incorporation, as required by the transactional
documents in our recent financing; -- the adequacy of the Company's
patents and proprietary rights; -- the impact of litigation that
has been brought against the Company and any proposed settlement of
such litigation; and -- the other risks described under Certain
Risks and Uncertainties Related to the Company's Business, as
contained in the Company's Annual Report on Form 10-K and Quarterly
Report on Form 10-Q. The Company does not undertake to update any
forward-looking statements. There are a number of factors that
could cause actual results and developments to differ materially.
For a discussion of those risks and uncertainties, please see the
Company's Annual Report on Form 10-K for 2007 and its most recent
quarterly report on Form 10-Q. CONTACT: Genta Investor Relations
DATASOURCE: Genta Incorporated CONTACT: Genta Investor Relations,
+1-908-286-3980, or Web site: http://www.genta.com/
http://www.genta.com/investorrelation/events.html
Copyright